Latest 10-K annual reports

Instacart (Maplebear Inc.) reported an 11% revenue increase to $3.74 billion in 2025, driven by higher orders and GTV, alongside a $60 million FTC settlement.

Allegiant Travel Company reported record airline-only operating revenue of $2.5 billion in 2025, a 4.3% increase year-over-year, while advancing its strategic acquisition of Sun Country Airlines and divesting Sunseeker Resort.

Northern Oil and Gas, Inc. reported a 1% increase in proved reserves for 2025, alongside a significant non-cash impairment charge due to declining oil prices, while increasing production and shareholder returns.

D-Wave Quantum Inc. announced a significant revenue increase of 179% to $24.6 million in 2025, driven by system sales and professional services, yet reported a net loss of $355.1 million, a 147% increase from the prior year, as it continues heavy investment in quantum computing R&D and strategic acquisitions.

Morgan Stanley Direct Lending Fund reports a decrease in net investment income and unrealized depreciation for 2025, alongside strategic portfolio adjustments and new joint venture formation.

Xenon Pharmaceuticals Inc. continues to advance its late-stage clinical pipeline, including azetukalner for epilepsy and depression, while reporting increased net losses and R&D expenses for fiscal year 2025.

Sunrun achieved significant revenue growth and a return to net income in 2025, driven by new system deployments and strategic solar-plus-storage offerings, despite evolving regulatory and macroeconomic challenges.

First Horizon Corporation announced a significant increase in net income and diluted EPS for 2025, driven by lower deposit pricing, higher loan balances, and strategic technology investments.

Bentley Systems, Incorporated announced robust financial results for fiscal year 2025, driven by subscription revenue growth and strategic investments in AI and digital twin technologies, alongside the appointment of James Lee as Chief Operating Officer.

Nautilus Biotechnology, a development-stage life sciences company, reported a net loss of $59.0 million for 2025 as it continues to invest heavily in its Nautilus Voyager™ proteomics platform, targeting a phased commercial launch in late 2026.

National Health Investors, Inc. (NHI) reported a 12.1% increase in total revenues to $375.6 million for the fiscal year ended December 31, 2025, driven by new acquisitions and growth in its Senior Housing Operating Portfolio (SHOP) segment.

Denali Therapeutics reports increased net losses in 2025, alongside significant clinical advancements for its TransportVehicle platform and key program updates, including a PDUFA extension for tividenofusp alfa.

Personalis, Inc. reported an 18% revenue decrease in 2025, driven by reduced enterprise sales, but strengthened its cash position and secured key Medicare coverage for its cancer diagnostic tests.

Americold Realty Trust, Inc. reported a net loss of $115.3 million for 2025, alongside strategic acquisitions and a dividend increase, despite declines in warehouse occupancy and segment revenues.

Criteo S.A. announced a 1% revenue increase in 2025, driven by Retail Media, alongside plans to transfer its legal domicile to Luxembourg.

Diamond Hill Investment Group reports a decrease in total revenue and operating income for 2025, driven by net cash outflows in equity strategies, while progressing towards a $175.00 per share cash merger with First Eagle Investment Management.

OPKO Health, Inc. reported a significantly wider net loss of $225.7 million in 2025, despite an improved operating loss and strategic divestitures aimed at streamlining its diagnostics business.

Castle Biosciences reported a net loss of $24.2 million in 2025, a significant reversal from the prior year's profit, despite a 3.7% increase in total net revenues driven by non-dermatologic tests.

Asure Software, Inc. announced its 2025 annual results, revealing significant revenue growth driven by its SaaS HCM solutions, alongside an increased net loss and strategic acquisitions.

Freshworks Inc. reported a significant return to net income profitability in 2025, alongside strong revenue growth and a new $400 million share repurchase program.

Fidus Investment Corporation's 2025 annual report highlights a growing investment portfolio, increased income, and strategic capital management, despite a slight dip in debt investment yield.

Ironwood Pharmaceuticals reports a decrease in 2025 collaborative revenue for LINZESS due to pricing and inventory shifts, while advancing its apraglutide program despite a required confirmatory Phase III trial.

NWPX Infrastructure, Inc. announced a 6.8% increase in net sales and a 3.5% rise in net income for 2025, alongside strategic acquisitions and robust water infrastructure market demand.

Nerdy Inc. reported a 6% decrease in 2025 revenue to $178.99 million, driven by lower Institutional revenue and a non-recurring state-funded program, despite growth in Consumer Learning Memberships and strategic AI investments.

EPAM Systems, Inc. announced a 15.4% revenue increase to $5.46 billion in 2025, while net income and diluted EPS decreased by 16.9% and 14.3% respectively, alongside a new $1 billion share repurchase program.

Tanger Inc. reported a significant increase in net income and FFO for 2025, driven by strategic acquisitions and improved rental rates, while proactively managing its debt profile.

Block, Inc. announced a 17% increase in gross profit to $10.4 billion for 2025, driven by Cash App and Square ecosystems, alongside a significant workforce reduction plan for 2026.

Anteris Technologies Global Corp. reported significant R&D investments and net losses in 2025, while successfully initiating its pivotal PARADIGM Trial and securing substantial capital raises in late 2025 and early 2026.

Payoneer Global Inc. reported an 8% increase in revenue to $1,052.8 million for the year ended December 31, 2025, driven by SMB growth and strategic acquisitions, despite a 40% decline in net income.

Omnicell reports a 7% increase in total revenues for 2025, driven by service growth and strategic investments in autonomous medication management, despite a significant drop in net income and reduced product bookings.